|Brief Description||Principal Investigator|
|The primary objective of this study is to evaluate safety and tolerability and select a recommended Phase 2 dose (RP2D) of ADXS31-164 in subjects with solid tumors that express HER2||Tan, Antoinette Roslyn|
|To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.||Kim, Edward Sanghyun|
|The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory.||Kaplan, Joel Adam|
|The purpose of this study is to evaluate the factors currently used for risk-group assignment (DNA content, MYCN copy number, and tumor histology) in patients with newly diagnosed neuroblastoma or ganglioneuroblastoma.||Kaplan, Joel Adam|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
The first part of the study will determine the feasibility of adding pazopanib in combination with radiation or chemoradiation in pediatric and adult patients newly diagnosed with unresected intermediate- and high-risk (Non-Rhabdomyosarcoma Soft Tissue Sarcomas) NRSTS.
The second part of the study will compare the rates of response of (1) preoperative pazopanib plus chemoradiation versus preoperative chemoradiation alone for potentially resectable > 5 cm, Grade 3 intermediate to high risk ch
|Kaplan, Joel Adam|
|To evaluate progression-free survival (PFS) with CMB305 (sequentially administered LV305 and G305) in combination with atezolizumab or with atezolizumab alone, in patients with locally advanced, relapsed, or metastatic sarcoma expressing NY-ESO-1||Livingston, Michael Balfour|
To assess the antitumor activity of nab-paclitaxel combined with gemcitabine in patients with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcoma using RECIST 1.1 criteria and progression-free survival.
|Oesterheld, Javier E|
|To compare the progression-free survival (PFS) of eligible subjects treated with regorafenib or placebo according to modified RECIST version 1.1.||Livingston, Michael Balfour|